The Food and Drug Administration (FDA) has approved Janssen’s single-tablet regimen for the treatment of HIV in adults, Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide). The tablet is approved for people who are starting antiretroviral (ARV) treatment for the first time as well as certain people who are switching from another HIV regimen and have a fully suppressed virus.















